Merck (MSD) announced that the European Commission approved Keytruda® (pembrolizumab) in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC). The announcement comes after positive results over several measures from the Phase 3 KEYNOTE-671 clinical trial.
The news follows US FDA approval for the same indication reported in 2023.